Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Oral sulfasalazine clinical efficacy:
1. Effective corrective ulcerative colitis considered To be of mild or moderate severity.
2. Sulfasalazine is less likely to be effective in treating severe colitis.
3. Both
4. Neither
Relapses of ulcerative colitis may be prevented by sulfasalazine administration.
1. True
2. False
Superior agent with respect to therapeutic efficacy in treating active proctitis and distal ulcerative colitis.
1. Topical mesalamine (suspension enema or wax suppository)
2. Topical hydrocortisone
3. Both equally effective
Concerning 5-acetylsalicylic acid (5-ASA) pharmacokinetics:
1. About a third of orally administered sulfasalazine is absorbed in the small intestine.
2. Sulfasalazine reaching the: will be activated (mesalamine) by bacterial enzymes.
3. Both
4. Neither
Concerning sulfasalazine adverse effects:
1. Side effects are likely related to the "sulfa" moiety
2. Dose-related side effects of social cells seen can be limited by either decreasing the dose or administering the medication with food.
3. Both
4. Neither
Sulfasalazine decreases intestinal folate absorption and accordingly is often administered with folate supplementation.
1. True
2. False
Diarrhea is most likely associated with this agent
1. Olsalazine
2. Mesalamine
3. Sulfasalazine
Lialda (methylmelamine) is a delayed-release tablet formulation.
1. True
2. False
Formulation least likely to be released in the small intestine:
1. Sulfasalazine
2. 5-ASA pH-dependent release (Lialda)
3. 5-ASA delayed-release capsule (Pentasa)
Hypersensitivity reaction(s) to sulfapyridine (or very occasionally, 5-ASA):
1. Exfoliative dermatitis
2. Fever
3. Pancreatitis
4. Hepatitis
5. A & B
6. A & C
7. A, B & C
8. A, B, C & D (all of the responses)

Medical Pharmacology: Gastrointestinal Pharmacology Practice Questions